

DECREASED SENSORY RECEPTORS P2X<sub>3</sub> AND TRPV1  
FOLLOWING INTRADETRUSOR INJECTIONS OF BOTULINUM  
TOXIN A OVERACTIVITY

Journal of Urology

174, 977-983

DOI: 10.1097/01.ju.0000169481.42259.54

Citation Report

#	ARTICLE	IF	CITATIONS
1	Therapy Insight: bladder dysfunction associated with multiple sclerosis. Nature Reviews Urology, 2005, 2, 492-501.	1.4	65
2	A COMPARISON BETWEEN THE RESPONSE OF PATIENTS WITH IDIOPATHIC DETRUSOR OVERACTIVITY AND NEUROGENIC DETRUSOR OVERACTIVITY TO THE FIRST INTRADETRUSOR INJECTION OF BOTULINUM-A TOXIN. Journal of Urology, 2005, 174, 984-989.	0.2	228
3	Experience With 100 Cases Treated With Botulinum-A Toxin Injections in the Detrusor Muscle for Idiopathic Overactive Bladder Syndrome Refractory to Anticholinergics. Journal of Urology, 2006, 176, 177-185.	0.2	234
4	Mechanisms of Disease: role of purinergic signaling in the pathophysiology of bladder dysfunction. Nature Reviews Urology, 2006, 3, 206-215.	1.4	60
5	The overactive bladder: review of current pharmacotherapy in adults. Part 2: treatment options in cases refractory to anticholinergics. Expert Opinion on Pharmacotherapy, 2006, 7, 529-538.	0.9	13
6	Advances in the development of TRPV1 antagonists. Expert Opinion on Therapeutic Patents, 2006, 16, 783-795.	2.4	14
7	Understanding the Role of Botulinum Toxin A in the Treatment of the Overactive Bladder—More than Just Muscle Relaxation. European Urology Supplements, 2006, 5, 670-678.	0.1	13
8	Efficacy of Botulinum Toxin A in the Treatment of Female Idiopathic Detrusor Overactivity Incontinence: Long-Term Results of a Prospective Nonrandomised Study. European Urology Supplements, 2006, 5, 685-690.	0.1	1
9	The Application of Botulinum Toxin in the Prostate. Journal of Urology, 2006, 176, 2375-2382.	0.2	80
10	Repeated Intradetrusor Botulinum Toxin Type A in Children With Neurogenic Bladder Due to Myelomeningocele. Journal of Urology, 2006, 175, 1102-1105.	0.2	96
11	Botulinum Toxin for the Management of Bladder Dysfunction. Drugs, 2006, 66, 1301-1318.	4.9	46
12	Will suburothelial injection of small dose of botulinum A toxin have similar therapeutic effects and less adverse events for refractory detrusor overactivity?. Urology, 2006, 68, 993-997.	0.5	70
13	Persistence of therapeutic effect after repeated injections of botulinum toxin type A to treat incontinence due to neurogenic detrusor overactivity. Urology, 2006, 68, 1193-1197.	0.5	99
16	The challenge of overactive bladder therapy: alternative to antimuscarinic agents. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2006, 32, 620-630.	0.7	14
17	Botulinum toxin for overactive bladder: reaching a happy median. Nature Reviews Urology, 2006, 3, 128-129.	1.4	1
18	Darifenacin: a selective M3 muscarinic receptor antagonist for the treatment of overactive bladder. Therapy: Open Access in Clinical Medicine, 2006, 3, 723-732.	0.2	3
19	Botulinum toxin in urinary incontinence. Current Opinion in Urology, 2006, 16, 255-260.	0.9	8
22	Anti-emetic therapy: updating urological cancer-care providers. BJU International, 2006, 97, 673-675.	1.3	1

#	ARTICLE	IF	CITATIONS
23	Phosphodiesterase-5 inhibitors help climbers to achieve new heights. BJU International, 2006, 97, 672-673.	1.3	2
24	The management of benign prostatic obstruction: a voice from the Third World. BJU International, 2006, 97, 671-672.	1.3	2
25	Techniques for the intradetrusor administration of botulinum toxin. BJU International, 2006, 97, 675-678.	1.3	22
26	Neuromodulatory therapies in female pelvic medicine and reconstructive surgery: biological agents. BJU International, 2006, 98, 50-60.	1.3	12
27	Developments in pharmacological therapy for the overactive bladder. BJU International, 2006, 98, 78-87.	1.3	8
28	The structure and mode of action of different botulinum toxins. European Journal of Neurology, 2006, 13, 1-9.	1.7	196
29	Botulinum toxin injection therapy in the management of lower urinary tract dysfunction. International Journal of Clinical Practice, 2006, 60, 1-7.	0.8	7
30	Refractory neurogenic detrusor overactivity. International Journal of Clinical Practice, 2006, 60, 22-26.	0.8	6
31	Treatment-resistant detrusor overactivity - underlying pharmacology and potential mechanisms. International Journal of Clinical Practice, 2006, 60, 8-16.	0.8	31
34	Small molecule vanilloid TRPV1 receptor antagonists approaching drug status: can they live up to the expectations?. Naunyn-Schmiedeberg's Archives of Pharmacology, 2006, 373, 273-286.	1.4	33
35	TRPV1 (vanilloid receptor) in the urinary tract: expression, function and clinical applications. Naunyn-Schmiedeberg's Archives of Pharmacology, 2006, 373, 287-299.	1.4	152
36	Botulinum neurotoxin "A" from laboratory to bedside. Neurotoxicity Research, 2006, 9, 133-140.	1.3	56
37	Proposed Mechanism for the Efficacy of Injected Botulinum Toxin in the Treatment of Human Detrusor Overactivity. European Urology, 2006, 49, 644-650.	0.9	294
38	Quality of Life Changes in Patients with Neurogenic versus Idiopathic Detrusor Overactivity after Intradetrusor Injections of Botulinum Neurotoxin Type A and Correlations with Lower Urinary Tract Symptoms and Urodynamic Changes. European Urology, 2006, 49, 528-535.	0.9	115
40	Effect of Intravesical Resiniferatoxin (RTX) on Lower Urinary Tract Symptoms, Urodynamic Parameters, and Quality of Life of Patients with Urodynamic Increased Bladder Sensation. European Urology, 2006, 50, 1299-1305.	0.9	71
42	Physiology and Pathophysiology of Purinergic Neurotransmission. Physiological Reviews, 2007, 87, 659-797.	13.1	1,396
43	The Uroepithelial-associated sensory web. Kidney International, 2007, 72, 1057-1064.	2.6	113
45	Manipulation of Signal Transduction by Botulinum Neurotoxins and their Derivatives. Current Signal Transduction Therapy, 2007, 2, 221-225.	0.3	0

#	ARTICLE	IF	CITATIONS
46	Developments in the pharmacotherapy of the overactive bladder. <i>Current Opinion in Urology</i> , 2007, 17, 223-230.	0.9	18
47	Botulinum Toxin B Is Not an Effective Treatment of Refractory Overactive Bladder. <i>Urology</i> , 2007, 69, 69-73.	0.5	21
48	Applications of Botulinum toxin in urogynaecology. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2007, 133, 4-11.	0.5	21
49	TRPs in bladder diseases. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2007, 1772, 879-884.	1.8	50
50	Botulinum toxin for detrusor overactivity and symptoms of overactive bladder: where we are now and where we are going. <i>Nature Reviews Urology</i> , 2007, 4, 379-386.	1.4	13
51	Efficacy and impact of botulinum toxin A on quality of life in patients with neurogenic detrusor overactivity. <i>Scandinavian Journal of Urology and Nephrology</i> , 2007, 41, 335-340.	1.4	128
52	Arthritis and pain. Future targets to control osteoarthritis pain. <i>Arthritis Research and Therapy</i> , 2007, 9, 212.	1.6	111
54	Botulinum Toxin Type A Injections Into the Trigone to Treat Idiopathic Overactive Bladder do Not Induce Vesicoureteral Reflux. <i>Journal of Urology</i> , 2007, 177, 1011-1014.	0.2	112
56	Comparison of Effectiveness of Detrusor, Suburothelial and Bladder Base Injections of Botulinum Toxin A for Idiopathic Detrusor Overactivity. <i>Journal of Urology</i> , 2007, 178, 1359-1363.	0.2	136
57	934 P2X 3 RECEPTOR-EXPRESSION IN FETAL AND INFANT BLADDERS - THE BASIS FOR A NEW THERAPEUTIC CONCEPT FOR OVERACTIVE BLADDERS IN CHILDREN. <i>European Urology Supplements</i> , 2007, 6, 256.	0.1	0
58	The Challenge of the Overactive Bladder: From Laboratory to New Drugs. <i>EAU-EBU Update Series</i> , 2007, 5, 250-258.	0.7	2
59	Botulinum toxin injection: a review of injection principles and protocols. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2007, 33, 132-141.	0.7	19
60	The molecular basis of urgency: regional difference of vanilloid receptor expression in the human urinary bladder. <i>Neurourology and Urodynamics</i> , 2007, 26, 433-438.	0.8	72
61	Resiniferatoxin and botulinum toxin type A for treatment of lower urinary tract symptoms. <i>Neurourology and Urodynamics</i> , 2007, 26, 920-927.	0.8	67
62	Lower urinary tract symptoms (LUTS) and bladder afferent activity. <i>Neurourology and Urodynamics</i> , 2007, 26, 908-913.	0.8	59
63	The vanilloid receptor TRPV1: 10 years from channel cloning to antagonist proof-of-concept. <i>Nature Reviews Drug Discovery</i> , 2007, 6, 357-372.	21.5	754
64	Botulinum toxin A in the overactive bladder: current status and future directions. <i>BJU International</i> , 2007, 99, 247-262.	1.3	73
65	BOTULINUM TOXIN A IN THE OVERACTIVE BLADDER: CURRENT STATUS AND FUTURE DIRECTIONS. <i>BJU International</i> , 2007, 99, 1549-1550.	1.3	1

#	ARTICLE	IF	CITATIONS
66	Persistence of the synaptosomal-associated protein-25 cleavage product after intradetrusor botulinum toxin A injections in patients with myelomeningocele showing an inadequate response to treatment. <i>BJU International</i> , 2007, 100, 070907033641006-???	1.3	30
67	Do Repeat Intradetrusor Botulinum Toxin Type A Injections Yield Valuable Results? Clinical and Urodynamic Results after Five Injections in Patients with Neurogenic Detrusor Overactivity. <i>European Urology</i> , 2007, 52, 1729-1735.	0.9	90
69	Update on use of botulinum toxin to treat overactive bladder. <i>Current Bladder Dysfunction Reports</i> , 2007, 2, 65-70.	0.2	0
70	Emerging pharmacological targets in overactive bladder therapy: experimental and clinical evidences. <i>International Urogynecology Journal</i> , 2008, 19, 583-598.	0.7	25
71	Botulinum toxin-A for idiopathic overactivity of the vesical detrusor: a 2-year follow-up. <i>International Urogynecology Journal</i> , 2008, 19, 905-909.	0.7	17
72	Therapeutic receptor targets for lower urinary tract dysfunction. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2008, 377, 437-448.	1.4	123
73	Afferents and lower urinary tract symptoms: Pathophysiology and future afferent therapy. <i>Current Bladder Dysfunction Reports</i> , 2008, 3, 217-223.	0.2	3
74	Future aspects of botulinum neurotoxins. <i>Journal of Neural Transmission</i> , 2008, 115, 567-573.	1.4	22
75	The use of botulinum neurotoxin type A (BoNTA) in urology. <i>Journal of Neural Transmission</i> , 2008, 115, 593-605.	1.4	30
76	On the origin of bladder sensing: Tr(i)ps in urology. <i>Neurourology and Urodynamics</i> , 2008, 27, 264-273.	0.8	117
77	The pharmacological challenge to tame the transient receptor potential vanilloidâ€1 (TRPV1) nociceptor. <i>British Journal of Pharmacology</i> , 2008, 155, 1145-1162.	2.7	152
78	The neural control of micturition. <i>Nature Reviews Neuroscience</i> , 2008, 9, 453-466.	4.9	1,171
79	Botulinum toxin type A inhibits sensory neuropeptide release in rat bladder models of acute injury and chronic inflammation. <i>BJU International</i> , 2008, 101, 366-370.	1.3	195
80	Botulinum toxin: future developments. <i>BJU International</i> , 2008, 102, 20-22.	1.3	9
81	Urinary Incontinence at Orgasm: Relation to Detrusor Overactivity and Treatment Efficacy. <i>European Urology</i> , 2008, 54, 911-917.	0.9	73
82	Editorial Comment on: Urinary Incontinence at Orgasm: Relation to Detrusor Overactivity and Treatment Efficacy. <i>European Urology</i> , 2008, 54, 915-916.	0.9	5
83	Early Effect on the Overactive Bladder Symptoms following Botulinum Neurotoxin Type A Injections for Detrusor Overactivity. <i>European Urology</i> , 2008, 54, 181-187.	0.9	52
84	Histological Changes in the Urothelium and Suburothelium of Human Overactive Bladder following Intradetrusor Injections of Botulinum Neurotoxin Type A for the Treatment of Neurogenic or Idiopathic Detrusor Overactivity. <i>European Urology</i> , 2008, 53, 1245-1253.	0.9	133

#	ARTICLE	IF	CITATIONS
85	Editorial Comment on: Histological Changes in the Urothelium and Suburothelium of Human Overactive Bladder Following Intradetrusor Injections of Botulinum Neurotoxin Type A for the Treatment of Neurogenic or Idiopathic Detrusor Overactivity. <i>European Urology</i> , 2008, 53, 1253.	0.9	0
86	Is Botulinum Neurotoxin Type A (BoNT-A) a Novel Therapy for Lower Urinary Tract Symptoms Due to Benign Prostatic Enlargement? A Review of the Literature. <i>European Urology</i> , 2008, 54, 765-777.	0.9	45
87	PROSTATE GROWTH AND PREVALENCE OF PROSTATE DISEASES IN EARLY ONSET SPINAL CORD INJURIES. <i>European Urology Supplements</i> , 2008, 7, 215.	0.1	11
88	Emerging drugs for treatment of overactive bladder and detrusor overactivity. <i>Expert Opinion on Emerging Drugs</i> , 2008, 13, 431-446.	1.0	19
89	Botulinum toxin type A normalizes alterations in urothelial ATP and NO release induced by chronic spinal cord injury. <i>Neurochemistry International</i> , 2008, 52, 1068-1075.	1.9	109
91	BOTULINUM TOXIN TYPE A NORMALIZES ALTERATIONS IN UROTHELIAL ATP AND NO RELEASE CAUSED BY CHRONIC SPINAL CORD INJURY. <i>Journal of Urology</i> , 2008, 179, 77-77.	0.2	0
92	Expression and function of rat urothelial P2Y receptors. <i>American Journal of Physiology - Renal Physiology</i> , 2008, 294, F821-F829.	1.3	54
93	Drug Insight: biological effects of botulinum toxin A in the lower urinary tract. <i>Nature Reviews Urology</i> , 2008, 5, 319-328.	1.4	108
94	Botulinum Toxin for Lower Urinary Tract Symptoms in Women. <i>Journal of Pelvic Medicine &amp; Surgery</i> , 2008, 14, 135-161.	0.1	0
95	Botulinum toxin in the treatment of overactive bladder. <i>Urologia</i> , 2008, 75, 4-13.	0.3	3
96	Pharmacological Modulation of Pain. , 2008, , 795-819.		1
97	Investigational Drug Therapies for Overactive Bladder Syndrome: The Potential Alternatives to Anticholinergics. <i>Urologia</i> , 2009, 76, 161-177.	0.3	1
98	Mechanism of Action of Botulinum Neurotoxin in the Lower Urinary Tract. , 2009, , 231-239.e1.		1
99	Botulinum Toxin in Overactive Bladder. , 2009, , 240-256.		1
100	Multiple sclerosis produces significant changes in urinary bladder innervation which are partially reflected in the lower urinary tract functional status-sensory nerve fibers role in detrusor overactivity. <i>Multiple Sclerosis Journal</i> , 2009, 15, 860-868.	1.4	13
101	Review: TRP family proteins in the lower urinary tract: translating basic science into new clinical prospective. <i>Therapeutic Advances in Urology</i> , 2009, 1, 33-42.	0.9	6
102	Differential Localizations of the Transient Receptor Potential Channels TRPV4 and TRPV1 in the Mouse Urinary Bladder. <i>Journal of Histochemistry and Cytochemistry</i> , 2009, 57, 277-287.	1.3	91
103	Prostate Growth and Prevalence of Prostate Diseases in Early Onset Spinal Cord Injuries. <i>European Urology</i> , 2009, 56, 142-150.	0.9	28

#	ARTICLE	IF	CITATIONS
104	Urinary Nerve Growth Factor Levels are Elevated in Patients with Detrusor Overactivity and Decreased in Responders to Detrusor Botulinum Toxin-A Injection. <i>European Urology</i> , 2009, 56, 700-707.	0.9	163
105	Mechanisms of Prostate Atrophy after Glandular Botulinum Neurotoxin Type A Injection: An Experimental Study in the Rat. <i>European Urology</i> , 2009, 56, 134-141.	0.9	50
106	Editorial Comment on: Mechanisms of Prostate Atrophy after Glandular Botulinum Neurotoxin Type A Injection: An Experimental Study in the Rat. <i>European Urology</i> , 2009, 56, 140-141.	0.9	1
107	Recommendations on the Use of Botulinum Toxin in the Treatment of Lower Urinary Tract Disorders and Pelvic Floor Dysfunctions: A European Consensus Report. <i>European Urology</i> , 2009, 55, 100-120.	0.9	269
108	Suburothelial Myofibroblasts in the Human Overactive Bladder and the Effect of Botulinum Neurotoxin Type A Treatment. <i>European Urology</i> , 2009, 55, 1440-1449.	0.9	74
109	A Refocus on the Bladder as the Originator of Storage Lower Urinary Tract Symptoms: A Systematic Review of the Latest Literature. <i>European Urology</i> , 2009, 56, 810-820.	0.9	107
110	Intravesical Botulinum Toxin Injection for Overactive Bladder—What We Can Learn From Previous Clinical Trials. <i>Tzu Chi Medical Journal</i> , 2009, 21, 277-284.	0.4	1
111	Botulinum toxin in paediatric urology: a systematic literature review. <i>Pediatric Surgery International</i> , 2009, 25, 19-23.	0.6	25
112	Is efficacy of repeated intradetrusor botulinum toxin type AA (Dysport®) injections dose dependent? Clinical and urodynamic results after four injections in patients with drug-resistant neurogenic detrusor overactivity. <i>International Urology and Nephrology</i> , 2009, 41, 805-813.	0.6	21
116	Where is TRPV1 expressed in the bladder, do we see the real channel?. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2009, 379, 421-425.	1.4	80
117	A morphological evaluation of botulinum neurotoxin A injections into the detrusor muscle using magnetic resonance imaging. <i>World Journal of Urology</i> , 2009, 27, 397-403.	1.2	58
118	Botulinum toxin type A reduces histamine-induced itch and vasomotor responses in human skin. <i>British Journal of Dermatology</i> , 2009, 161, 737-745.	1.4	63
119	Expression of purinergic P2X2-receptors in neurogenic bladder dysfunction due to spinal cord injury: a preliminary immunohistochemical study. <i>Spinal Cord</i> , 2009, 47, 561-564.	0.9	15
120	Decrease of urinary nerve growth factor levels after antimuscarinic therapy in patients with overactive bladder. <i>BJU International</i> , 2009, 103, 1668-1672.	1.3	101
121	Comparison of intravesical botulinum toxin type A injections plus hydrodistention with hydrodistention alone for the treatment of refractory interstitial cystitis/painful bladder syndrome. <i>BJU International</i> , 2009, 104, 657-661.	1.3	166
122	Purines and Sensory Nerves. <i>Handbook of Experimental Pharmacology</i> , 2009, , 333-392.	0.9	78
123	Basic and clinical aspects of BOTOX®. <i>Toxicon</i> , 2009, 54, 676-682.	0.8	18
124	Botulinum toxin and refractory non-neurogenic overactive detrusor. <i>Annals of Physical and Rehabilitation Medicine</i> , 2009, 52, 668-683.	1.1	2

#	ARTICLE	IF	CITATIONS
125	Subcutaneous Botulinum toxin type A reduces capsaicin-induced trigeminal pain and vasomotor reactions in human skin. <i>Pain</i> , 2009, 141, 60-69.	2.0	146
126	Acid-Sensitive Ion Channels and Receptors. <i>Handbook of Experimental Pharmacology</i> , 2009, , 283-332.	0.9	234
127	Functional Transient Receptor Potential Vanilloid 1 is Expressed in Human Urothelial Cells. <i>Journal of Urology</i> , 2009, 182, 2944-2950.	0.2	61
129	Cadherin-11 Up-Regulation in Overactive Bladder Suburothelial Myofibroblasts. <i>Journal of Urology</i> , 2009, 182, 190-195.	0.2	15
130	Afferent Nerve Regulation of Bladder Function in Health and Disease. <i>Handbook of Experimental Pharmacology</i> , 2009, , 91-138.	0.9	223
131	Recent Advances in Intravesical Treatment of Overactive Bladder. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2009, 1, 2-9.	0.6	1
132	Bladder Botulinum Toxin. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2009, 1, S22.	0.6	1
133	Urodynamic and Immunohistochemical Evaluation of Intravesical Botulinum Toxin A Delivery Using Liposomes. <i>Journal of Urology</i> , 2009, 182, 786-792.	0.2	118
134	Perspective of Botox for treatment of male lower urinary tract symptoms. <i>Current Opinion in Urology</i> , 2009, 19, 20-25.	0.9	8
135	Has botulinum toxin therapy come of age: what do we know, what do we need to know, and should we use it?. <i>Current Opinion in Urology</i> , 2009, 19, 347-352.	0.9	17
136	Botulinum neurotoxin A for benign prostatic hyperplasia. <i>Current Opinion in Urology</i> , 2010, 20, 28-36.	0.9	13
139	The Overactive Bladder: New Concepts of Etiology and Treatment. <i>Current Bladder Dysfunction Reports</i> , 2010, 5, 126-134.	0.2	0
140	In the Human Urothelium and Suburothelium, Intradetrusor Botulinum Neurotoxin Type A Does Not Induce Apoptosis: Preliminary Results. <i>European Urology</i> , 2010, 57, 879-883.	0.9	11
141	Effects of stimulation of muscarinic receptors on bladder afferent nerves in the in vitro bladderâ€œpelvic afferent nerve preparation of the rat. <i>Brain Research</i> , 2010, 1361, 43-53.	1.1	23
142	Changes in afferent activity after spinal cord injury. <i>Neurourology and Urodynamics</i> , 2010, 29, 63-76.	0.8	140
143	Is the urothelium intelligent?. <i>Neurourology and Urodynamics</i> , 2010, 29, 598-602.	0.8	53
144	Botulinum toxin for the lower urinary tract. <i>BJU International</i> , 2010, 105, 1046-1058.	1.3	27
145	The role of the transient receptor potential (TRP) superfamily of cationâ€œselective channels in the management of the overactive bladder. <i>BJU International</i> , 2010, 106, 1114-1127.	1.3	95



#	ARTICLE	IF	CITATIONS
146	Study of Botulinum Toxin A in Neurogenic Bladder Due to Spina Bifida in Children. ANZ Journal of Surgery, 2010, 80, 250-253.	0.3	17
147	Neurogenic bladder dysfunction: pharmacological interventional approaches. , 0, , 89-111.		2
148	Targeted Secretion Inhibitorsâ€™ Innovative Protein Therapeutics. Toxins, 2010, 2, 2795-2815.	1.5	38
149	The overactive bladder. Therapeutic Advances in Urology, 2010, 2, 147-155.	0.9	13
150	Urine and Serum C-Reactive Protein Levels as Potential Biomarkers of Lower Urinary Tract Symptoms. Urological Science, 2010, 21, 132-136.	0.2	34
151	Intravesical Injections of Botulinum Toxin Type A for Management of Neuropathic Bladder: A Comparison of Two Methods. Urology, 2010, 76, 225-230.	0.5	30
152	Urinary Nerve Growth Factor Levels in Overactive Bladder Syndrome and Lower Urinary Tract Disorders. Journal of the Formosan Medical Association, 2010, 109, 862-878.	0.8	50
153	Immunohistochemical Expression of Muscarinic Receptors in the Urothelium and Suburothelium of Neurogenic and Idiopathic Overactive Human Bladders, and Changes With Botulinum Neurotoxin Administration. Journal of Urology, 2010, 184, 2578-2585.	0.2	59
154	Pharmacotherapy of overactive bladder: epidemiology and pathophysiology of overactive bladder. Expert Opinion on Pharmacotherapy, 2011, 12, 1017-1027.	0.9	15
155	Botulinum toxin in the failure of high urinary diversion closure. Actas UrolÃ³gicas EspaÃ±olas (English) Tj ETQq1 1 0,784314 rgBT /Over	0,2	6
156	Pharmacotherapy for overactive bladder: minimally invasive treatment â€™ botulinum toxins. Expert Opinion on Pharmacotherapy, 2011, 12, 1029-1039.	0.9	5
158	Updates on the antinociceptive mechanism hypothesis of botulinum toxin A. Parkinsonism and Related Disorders, 2011, 17, S28-S33.	1.1	109
159	Effect of Botulinum Toxin on Expression of Nerve Growth Factor and Transient Receptor Potential Vanilloid 1 in Urothelium and Detrusor Muscle of Rats With Bladder Outlet Obstruction-induced Detrusor Overactivity. Urology, 2011, 78, 721.e1-721.e6.	0.5	38
161	Promise of Urinary Nerve Growth Factor for Assessment of Overactive Bladder Syndrome. LUTS: Lower Urinary Tract Symptoms, 2011, 3, 2-9.	0.6	9
162	Botulinum A Toxin Intravesical Injections in the Treatment of Refractory Overactive Bladder in Patients with Parkinson's Disease. , 0, , .		0
163	Increased levels of SV2A botulinum neurotoxin receptor in clinical sensory disorders and functional effects of botulinum toxins A and E in cultured human sensory neurons. Journal of Pain Research, 2011, 4, 347.	0.8	25
164	Spinal Cord Injury and Bladder Dysfunction: New Ideas about an Old Problem. Scientific World Journal, The, 2011, 11, 214-234.	0.8	54
165	The afferent system and its role in lower urinary tract dysfunction. Current Opinion in Urology, 2011, 21, 268-274.	0.9	43

#	ARTICLE	IF	CITATIONS
166	The safety and efficacy of botulinum toxin-A in the management of bladder oversensitivity: a randomised double-blind placebo-controlled trial. <i>International Journal of Clinical Practice</i> , 2011, 65, 698-704.	0.8	32
167	Afferent Mechanism in the Urinary Tract. <i>Handbook of Experimental Pharmacology</i> , 2011, , 171-205.	0.9	35
169	Intravesical instillation of botulinum toxin A: an in vivo murine study and pilot clinical trial. <i>International Urology and Nephrology</i> , 2011, 43, 337-343.	0.6	24
170	Women's perspective of botulinum toxin treatment for overactive bladder symptoms. <i>International Urogynecology Journal</i> , 2011, 22, 425-431.	0.7	8
171	What Is the Evidence for the Use of Botulinum Toxin in Idiopathic Detrusor Overactivity?. <i>Current Bladder Dysfunction Reports</i> , 2011, 6, 70-73.	0.2	0
172	Multifactorial causes of irritating bladder symptoms in patients with Sjögren's syndrome. <i>Neurourology and Urodynamics</i> , 2011, 30, 97-101.	0.8	9
173	Urodynamic results and clinical outcomes with intradetrusor injections of onabotulinumtoxinA in a randomized, placebo-controlled dose-finding study in idiopathic overactive bladder. <i>Neurourology and Urodynamics</i> , 2011, 30, 556-562.	0.8	137
174	Increased transient receptor potential vanilloid type 1 (TRPV1) signaling in idiopathic overactive bladder urothelial cells. <i>Neurourology and Urodynamics</i> , 2011, 30, 606-611.	0.8	34
175	Bladder base/trigone injection is safe and as effective as bladder body injection of onabotulinumtoxinA for idiopathic detrusor overactivity refractory to antimuscarinics. <i>Neurourology and Urodynamics</i> , 2011, 30, 1242-1248.	0.8	72
176	Increased serum nerve growth factor levels in patients with overactive bladder syndrome refractory to antimuscarinic therapy. <i>Neurourology and Urodynamics</i> , 2011, 30, 1525-1529.	0.8	57
177	Reduction of urgency severity is associated with long-term therapeutic effect after intravesical onabotulinumtoxinA injection for idiopathic detrusor overactivity. <i>Neurourology and Urodynamics</i> , 2011, 30, 1497-1502.	0.8	25
178	Does Finasteride Have a Preventive Effect on Chronic Bacterial Prostatitis? Pilot Study Using an Animal Model. <i>Urologia Internationalis</i> , 2011, 86, 204-209.	0.6	14
179	TRPA1 receptor modulation attenuates bladder overactivity induced by spinal cord injury. <i>American Journal of Physiology - Renal Physiology</i> , 2011, 300, F1223-F1234.	1.3	78
180	Prospective randomized trial of 100u vs 200u botox in the treatment of idiopathic overactive bladder. <i>Urology Annals</i> , 2011, 3, 66.	0.3	31
181	Urothelial TRPV1: TRPV1-Reporter Mice, a Way to Clarify the Debate?. <i>Frontiers in Physiology</i> , 2012, 3, 130.	1.3	4
182	Novel treatments of interstitial cystitis/bladder pain syndrome based on pathophysiology. <i>Clinical Investigation</i> , 2012, 2, 1085-1100.	0.0	3
183	Treatment of Overactive Bladder Symptoms beyond Antimuscarinics: Current and Future Therapies. <i>Postgraduate Medicine</i> , 2012, 124, 16-27.	0.9	8
184	Controversy over the pharmacological treatments of storage symptoms in spinal cord injury patients: a literature overview. <i>Spinal Cord</i> , 2012, 50, 8-13.	0.9	23

#	ARTICLE	IF	CITATIONS
185	Afferent Pathways Arising from the Lower Urinary Tract after Complete Spinal Cord Injury or Cauda Equina Lesion: Clinical Observations with Neurophysiological Implications. <i>Urologia Internationalis</i> , 2012, 89, 462-467.	0.6	14
186	Botulinum toxin type A-induced changes in the chemical coding of dorsal root ganglion neurons supplying the porcine urinary bladder. <i>Polish Journal of Veterinary Sciences</i> , 2012, 15, 345-353.	0.2	25
187	Single Application of A2 NTX, a Botulinum Toxin A2 Subunit, Prevents Chronic Pain Over Long Periods in Both Diabetic and Spinal Cord Injury-Induced Neuropathic Pain Models. <i>Journal of Pharmacological Sciences</i> , 2012, 119, 282-286.	1.1	19
188	Intravesical treatments of bladder pain syndrome/interstitial cystitis. <i>Nature Reviews Urology</i> , 2012, 9, 707-720.	1.9	49
189	Difficult Urination Does Not Affect the Successful Outcome after 100U OnabotulinumtoxinA Intravesical Injection in Patients with Idiopathic Detrusor Overactivity. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2012, 4, 29-34.	0.6	3
190	Botulinum Neurotoxin Serotype A Suppresses Neurotransmitter Release from Afferent as Well as Efferent Nerves in the Urinary Bladder. <i>European Urology</i> , 2012, 62, 1157-1164.	0.9	71
191	Intravesical Botulinum Toxin for Overactive Bladder Syndrome without Detrusor Overactivity. <i>British Journal of Medical and Surgical Urology</i> , 2012, 5, 169-173.	0.2	3
192	Reduction of TRPV1 expression in the trigeminal system by botulinum neurotoxin type-A. <i>Neurobiology of Disease</i> , 2012, 48, 367-378.	2.1	125
193	Differences in Mast Cell Infiltration, E-cadherin, and Zonula Occludens-1 Expression Between Patients With Overactive Bladder and Interstitial Cystitis/Bladder Pain Syndrome. <i>Urology</i> , 2012, 80, 225.e13-225.e18.	0.5	100
194	TRP Channels in the Genitourinary Tract. <i>Methods in Pharmacology and Toxicology</i> , 2012, , 373-395.	0.1	0
195	Neurotrophins as regulators of urinary bladder function. <i>Nature Reviews Urology</i> , 2012, 9, 628-637.	1.9	78
196	Drug development for LUTS – The challenge for industry. <i>Drug Discovery Today: Therapeutic Strategies</i> , 2012, 9, e5-e14.	0.5	2
197	Do baseline urodynamic parameters affect the treatment outcome after intravesical 100 U onabotulinumtoxinA injection in patients with idiopathic detrusor overactivity?. <i>Tzu Chi Medical Journal</i> , 2012, 24, 121-126.	0.4	2
198	Differential Effects of Botulinum Neurotoxin A on Bladder Contractile Responses to Activation of Efferent Nerves, Smooth Muscles and Afferent Nerves in Rats. <i>Journal of Urology</i> , 2012, 188, 1993-1999.	0.2	18
199	Pathologic mechanism of the therapeutic effect of botulinum toxin A on interstitial cystitis and painful bladder syndrome. <i>Tzu Chi Medical Journal</i> , 2012, 24, 170-177.	0.4	2
200	Intradetrusor versus suburothelial onabotulinumtoxinA injections for neurogenic detrusor overactivity: a pilot study. <i>Spinal Cord</i> , 2012, 50, 904-907.	0.9	33
201	Sensory Nerves. , 2012, , 583-625.		0
202	Sensory Dysfunction of Bladder Mucosa and Bladder Oversensitivity in a Rat Model of Metabolic Syndrome. <i>PLoS ONE</i> , 2012, 7, e45578.	1.1	39

#	ARTICLE	IF	CITATIONS
203	OnabotulinumtoxinA in the treatment of neurogenic bladder. <i>Biologics: Targets and Therapy</i> , 2012, 6, 299.	3.0	4
204	Botulinum Neurotoxin Type A for the Treatment of Benign Prostatic Hyperplasia: Randomized Study Comparing Two Doses. <i>Scientific World Journal, The</i> , 2012, 2012, 1-6.	0.8	15
205	Plasticity in reflex pathways to the lower urinary tract following spinal cord injury. <i>Experimental Neurology</i> , 2012, 235, 123-132.	2.0	123
206	Volume Matters: Bladder Injections of Botulinum Toxin Type A. <i>European Urology</i> , 2012, 61, 1185-1186.	0.9	7
207	Potential Biomarkers Utilized to Define and Manage Overactive Bladder Syndrome. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2012, 4, 32-41.	0.6	15
208	Transient receptor potential vanilloid 1 mediates nerve growth factor-induced bladder hyperactivity and noxious input. <i>BJU International</i> , 2012, 110, E422-8.	1.3	27
210	Botulinum toxin injection for lower urinary tract dysfunction. <i>International Journal of Urology</i> , 2013, 20, 40-55.	0.5	27
211	Botulinum Toxin A Detrusor Injections Reduce Postsynaptic Muscular M2, M3, P2X2, and P2X3 Receptors in Children and Adolescents Who Have Neurogenic Detrusor Overactivity: A Single-blind Study. <i>Urology</i> , 2013, 81, 1052-1057.	0.5	37
212	Tension-Free Vaginal Tape Plus Intradetrusor BOTOX <sup>®</sup> Injection Versus Tension-Free Vaginal Tape Versus Intradetrusor BOTOX Injection in Equal-Weight Mixed Urinary Incontinence: A Prospective Randomized Study. <i>Journal of Gynecologic Surgery</i> , 2013, 29, 235-240.	0.0	1
213	Repeated intravesical onabotulinumtoxinA injections are effective in treatment of refractory interstitial cystitis/bladder pain syndrome. <i>International Journal of Clinical Practice</i> , 2013, 67, 427-434.	0.8	33
214	Submucosal Administration of OnabotulinumtoxinA in the Treatment of Neurogenic Detrusor Overactivity: Pilot Single-Centre Experience and Comparison with Standard Injection into the Detrusor. <i>Urologia Internationalis</i> , 2013, 91, 423-428.	0.6	13
215	Principios de acción e indicaciones de la toxina botulínica en el tratamiento de la hiperactividad vesical del adulto. <i>EMC - Urología</i> , 2013, 45, 1-12.	0.0	0
216	OnabotulinumtoxinA for the Treatment of Patients with Overactive Bladder and Urinary Incontinence: Results of a Phase 3, Randomized, Placebo Controlled Trial. <i>Journal of Urology</i> , 2013, 189, 2186-2193.	0.2	347
217	Onabotulinumtoxin-A intradetrusorial injections modulate bladder expression of NGF, TrkA, p75 and TRPV1 in patients with detrusor overactivity. <i>Pharmacological Research</i> , 2013, 68, 118-124.	3.1	29
218	Potential urine and serum biomarkers for patients with overactive bladder and interstitial cystitis/bladder pain syndrome. <i>Tzu Chi Medical Journal</i> , 2013, 25, 13-18.	0.4	6
219	Common theme for drugs effective in overactive bladder treatment: Inhibition of afferent signaling from the bladder. <i>International Journal of Urology</i> , 2013, 20, 21-27.	0.5	30
220	Botulinum toxin-A for the treatment of overactive bladder: UK contributions. <i>Journal of Clinical Urology</i> , 2013, 6, 77-83.	0.1	6
221	Different types of toxins targeting TRPV1 in pain. <i>Toxicon</i> , 2013, 71, 66-75.	0.8	19

#	ARTICLE	IF	CITATIONS
222	Use of botulinum toxin in individuals with neurogenic detrusor overactivity: State of the art review. <i>Journal of Spinal Cord Medicine</i> , 2013, 36, 402-419.	0.7	53
223	Male incontinence. <i>Current Opinion in Urology</i> , 2013, 23, 545-551.	0.9	5
224	Angiotensin II type 2 receptor (AT <sub>2</sub> R) localization and antagonist-mediated inhibition of capsaicin responses and neurite outgrowth in human and rat sensory neurons. <i>European Journal of Pain</i> , 2013, 17, 1012-1026.	1.4	87
225	Botulinum Toxin Type A Reduces Hyperalgesia and TRPV1 Expression in Rats with Neuropathic Pain. <i>Pain Medicine</i> , 2013, 14, 276-286.	0.9	47
226	Bladder Pain Syndrome. , 2013, , .		5
227	New developments in the management of overactive bladder: focus on mirabegron and onabotulinumtoxinA. <i>Therapeutics and Clinical Risk Management</i> , 2013, 9, 161.	0.9	44
228	Intrapouch injections of botulinum toxin type A for the management of unit contractions of a continent urinary diversion. <i>Canadian Urological Association Journal</i> , 2013, 2, 417.	0.3	2
229	Increased Serum Adipokines Implicate Chronic Inflammation in the Pathogenesis of Overactive Bladder Syndrome Refractory to Antimuscarinic Therapy. <i>PLoS ONE</i> , 2013, 8, e76706.	1.1	27
230	Emerging treatments for overactive bladder: clinical potential of botulinum toxins. <i>Research and Reports in Urology</i> , 2014, 6, 51.	0.6	9
231	Neurogenic overactive bladder in spinal cord injury and multiple sclerosis: role of onabotulinumtoxinA. <i>Degenerative Neurological and Neuromuscular Disease</i> , 2014, 4, 65.	0.7	5
232	Selective inhibition of meningeal nociceptors by botulinum neurotoxin type A: Therapeutic implications for migraine and other pains. <i>Cephalalgia</i> , 2014, 34, 853-869.	1.8	187
233	Neural Control of the Lower Urinary Tract. , 2015, 5, 327-396.		337
234	Targets for botulinum toxin in the lower urinary tract. <i>Neurourology and Urodynamics</i> , 2014, 33, 31-38.	0.8	66
235	Chapter 2: Pathophysiology of neurogenic detrusor overactivity and the symptom complex of "Overactive bladder". <i>Neurourology and Urodynamics</i> , 2014, 33, S6-13.	0.8	47
236	Brain-derived neurotrophic factor in urinary continence and incontinence. <i>Nature Reviews Urology</i> , 2014, 11, 579-588.	1.9	24
237	Neuroanatomy, Neurophysiology, and Dysfunction of the Female Lower Urinary Tract. <i>Female Pelvic Medicine and Reconstructive Surgery</i> , 2014, 20, 65-75.	0.6	11
239	Pathophysiology and animal modeling of underactive bladder. <i>International Urology and Nephrology</i> , 2014, 46, 11-21.	0.6	54
240	Development of onabotulinumtoxinA for chronic migraine. <i>Annals of the New York Academy of Sciences</i> , 2014, 1329, 67-80.	1.8	44

#	ARTICLE	IF	CITATIONS
241	Neural Mechanisms Underlying Lower Urinary Tract Dysfunction. Korean Journal of Urology, 2014, 55, 81.	1.2	26
242	Signalling Molecules in the Urothelium. BioMed Research International, 2014, 2014, 1-14.	0.9	43
243	Pilot Study of Liposome-encapsulated OnabotulinumtoxinA for Patients with Overactive Bladder: A Single-center Study. European Urology, 2014, 65, 1117-1124.	0.9	100
244	Purinergic signalling in the urinary tract in health and disease. Purinergic Signalling, 2014, 10, 103-155.	1.1	137
245	Mechanism of action of onabotulinumtoxinA on lower urinary tract dysfunction. Tzu Chi Medical Journal, 2014, 26, 1-4.	0.4	2
246	Sacral Neuromodulation for Refractory Overactive Bladder, Interstitial Cystitis, and Painful Bladder Syndrome. Neurosurgery Clinics of North America, 2014, 25, 33-46.	0.8	35
247	Central nervous targets for the treatment of bladder dysfunction. Neurourology and Urodynamics, 2014, 33, 59-66.	0.8	33
248	Bladder Instillation of Liposome Encapsulated OnabotulinumtoxinA Improves Overactive Bladder Symptoms: A Prospective, Multicenter, Double-Blind, Randomized Trial. Journal of Urology, 2014, 192, 1743-1749.	0.2	88
249	Chapter 3: Molecular basis for the therapeutic effectiveness of botulinum neurotoxin type A. Neurourology and Urodynamics, 2014, 33, S14-20.	0.8	23
250	OnabotulinumtoxinA 100U provides significant improvements in overactive bladder symptoms in patients with urinary incontinence regardless of the number of anticholinergic therapies used or reason for inadequate management of overactive bladder. International Journal of Clinical Practice, 2014, 68, 1246-1256.	0.8	56
251	Neurotrophins in bladder function: What do we know and where do we go from here?. Neurourology and Urodynamics, 2014, 33, 39-45.	0.8	58
252	OnabotulinumtoxinA (Botox®): A Review of its Use in the Treatment of Urinary Incontinence in Patients with Multiple Sclerosis or Subcervical Spinal Cord Injury. Drugs, 2014, 74, 1659-1672.	4.9	15
253	Transient Receptor Potential Channels as Drug Targets: From the Science of Basic Research to the Art of Medicine. Pharmacological Reviews, 2014, 66, 676-814.	7.1	440
254	Botulinum Toxin A Injections for Non-neurogenic Overactive Bladder. Current Bladder Dysfunction Reports, 2014, 9, 254-260.	0.2	0
255	Botulinum Toxin A's Expanding Role in the Management of Pediatric Lower Urinary Tract Dysfunction. Current Urology Reports, 2014, 15, 426.	1.0	25
256	Potential urine and serum biomarkers for patients with bladder pain syndrome/interstitial cystitis. International Journal of Urology, 2014, 21, 34-41.	0.5	64
257	Botulinum toxin type A selectivity for certain types of pain is associated with capsaicin-sensitive neurons. Pain, 2014, 155, 1516-1526.	2.0	58
258	Botulinum toxin A, brain and pain. Progress in Neurobiology, 2014, 119-120, 39-59.	2.8	137

#	ARTICLE	IF	CITATIONS
259	OnabotulinumtoxinA for the treatment of overactive bladder. <i>Clinical Investigation</i> , 2014, 4, 281-286.	0.0	0
263	Botulinum Toxin as a Pain Killer: Players and Actions in Antinociception. <i>Toxins</i> , 2015, 7, 2435-2453.	1.5	39
264	Botulinum Toxin Type A Induces Changes in the Chemical Coding of Substance P-Immunoreactive Dorsal Root Ganglia Sensory Neurons Supplying the Porcine Urinary Bladder. <i>Toxins</i> , 2015, 7, 4797-4816.	1.5	17
265	Does Reduction of Number of Intradetrusor Injection Sites of aboBoNTA (Dysport®) Impact Efficacy and Safety in a Rat Model of Neurogenic Detrusor Overactivity?. <i>Toxins</i> , 2015, 7, 5462-5471.	1.5	2
266	Social stress in mice induces urinary bladder overactivity and increases TRPV1 channel-dependent afferent nerve activity. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2015, 309, R629-R638.	0.9	38
267	Changes in chemical coding of sympathetic chain ganglia (SChG) neurons supplying porcine urinary bladder after botulinum toxin (BTX) treatment. <i>Cell and Tissue Research</i> , 2015, 360, 263-272.	1.5	13
268	Intravesical Capsaicin and Resiniferatoxin for Bladder Disorders. , 2015, , 119-127.		0
269	Analgesic effects of botulinum neurotoxin type A in a model of allyl isothiocyanate- and capsaicin-induced pain in mice. <i>Toxicon</i> , 2015, 94, 23-28.	0.8	20
271	Current and potential urological applications of botulinum toxin A. <i>Nature Reviews Urology</i> , 2015, 12, 519-533.	1.9	31
272	The safety and efficiency of onabotulinumtoxinA for the treatment of overactive bladder: a systematic review and meta-analysis. <i>International Urology and Nephrology</i> , 2015, 47, 1779-1788.	0.6	22
273	Treatment of Bladder Pain Syndrome and Interstitial Cystitis: A Systematic Review. <i>Journal of Minimally Invasive Gynecology</i> , 2015, 22, S244.	0.3	1
274	Effect of botulinum toxin A on urothelial-release of ATP and expression of SNARE targets within the urothelium. <i>Neurourology and Urodynamics</i> , 2015, 34, 79-84.	0.8	61
275	New pharmacotherapy for treating overactive bladder: mirabegron and botulinum toxin. <i>Journal of the Korean Medical Association</i> , 2016, 59, 795.	0.1	0
276	Botulinum toxin A for the Treatment of Overactive Bladder. <i>Toxins</i> , 2016, 8, 59.	1.5	39
277	Botulinum Toxin A and Lower Urinary Tract Dysfunction: Pathophysiology and Mechanisms of Action. <i>Toxins</i> , 2016, 8, 120.	1.5	33
278	Structural and Functional Interactions between Transient Receptor Potential Vanilloid Subfamily 1 and Botulinum Neurotoxin Serotype A. <i>PLoS ONE</i> , 2016, 11, e0143024.	1.1	19
279	Botulinum Toxin A for Bladder Pain Syndrome/Interstitial Cystitis. <i>Toxins</i> , 2016, 8, 201.	1.5	21
280	Do we understand how botulinum toxin works and have we optimized the way it is administered to the bladder? ICI-RS 2014. <i>Neurourology and Urodynamics</i> , 2016, 35, 293-298.	0.8	20

#	ARTICLE	IF	CITATIONS
281	Retrograde transport of radiolabelled botulinum neurotoxin type A to the <scp>CNS</scp> after intradetrusor injection in rats. <i>BJU International</i> , 2016, 117, 697-704.	1.3	32
282	Efficacy and safety of botulinum toxin injection for interstitial cystitis/bladder pain syndrome: a systematic review and meta-analysis. <i>International Urology and Nephrology</i> , 2016, 48, 1215-1227.	0.6	24
283	What is the role of onabotulinumtoxinA for the management of the overactive bladder symptom complex in 2016?. <i>Urologia Colombiana</i> , 2016, 25, 72-74.	0.0	0
284	¿Cuál es el papel de la onabotulinumtoxinA para el tratamiento del complejo de síntomas de vejiga hiperactiva en 2016?. <i>Urologia Colombiana</i> , 2016, 25, 69-71.	0.0	1
285	Anorectal and Pelvic Pain. <i>Mayo Clinic Proceedings</i> , 2016, 91, 1471-1486.	1.4	56
286	Posible mecanismo de acción de la neuromodulación tibial en la hiperactividad del detrusor. Papel de las interneuronas. <i>Revista Mexicana De Urologia</i> , 2016, 76, 229-236.	0.0	2
287	Potential Future Pharmacological Treatment of Bladder Dysfunction. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2016, 119, 75-85.	1.2	61
288	Management of refractory overactive bladder. <i>The Obstetrician and Gynaecologist</i> , 2016, 18, 173-181.	0.2	5
289	Characterizing the Bladder's Response to Onabotulinum Toxin Type A Using a Rat Model. <i>Female Pelvic Medicine and Reconstructive Surgery</i> , 2016, 22, 467-471.	0.6	0
290	OnabotulinumtoxinA Treatment for Overactive Bladder in the Elderly: Practical Points and Future Prospects. <i>Drugs and Aging</i> , 2016, 33, 1-9.	1.3	5
291	Ten years of experience with intravesical and intrasphincteric onabotulinumtoxinA in children. <i>Journal of Pediatric Urology</i> , 2016, 12, 94.e1-94.e6.	0.6	40
292	Reduction in Bladder-Related Autonomic Dysreflexia after OnabotulinumtoxinA Treatment in Spinal Cord Injury. <i>Journal of Neurotrauma</i> , 2016, 33, 1651-1657.	1.7	34
293	Urodynamic and Immunohistochemical Evaluation of Intravesical Botulinum Toxin A Delivery Using Low Energy Shock Waves. <i>Journal of Urology</i> , 2016, 196, 599-608.	0.2	39
294	Investigational drugs for bladder pain syndrome (BPS) / interstitial cystitis (IC). <i>Expert Opinion on Investigational Drugs</i> , 2016, 25, 521-529.	1.9	22
295	Pathophysiology and Animal Modeling of Underactive Bladder. , 2016, , 51-68.		1
296	Mucosal signaling in the bladder. <i>Autonomic Neuroscience: Basic and Clinical</i> , 2016, 200, 49-56.	1.4	17
297	Advances in intravesical therapy for urinary tract disorders. <i>Expert Opinion on Drug Delivery</i> , 2016, 13, 71-84.	2.4	27
298	Treatment of bladder pain syndrome and interstitial cystitis: a systematic review. <i>International Urogynecology Journal</i> , 2016, 27, 697-708.	0.7	29



#	ARTICLE	IF	CITATIONS
299	Intravesical botulinum toxinâ€A injections reduce bladder pain of interstitial cystitis/bladder pain syndrome refractory to conventional treatment â€“ A prospective, multicenter, randomized, doubleâ€blind, placeboâ€controlled clinical trial. <i>Neurourology and Urodynamics</i> , 2016, 35, 609-614.	0.8	99
300	Reduction of urgency severity is the most important factor in the subjective therapeutic outcome of intravesical onabotulinumtoxinA injection for overactive bladder. <i>Neurourology and Urodynamics</i> , 2017, 36, 338-343.	0.8	6
301	Localized inhibition of P2X7R at the spinal cord injury site improves neurogenic bladder dysfunction by decreasing urothelial P2X3R expression in rats. <i>Life Sciences</i> , 2017, 171, 60-67.	2.0	22
302	The effect of intradetrusor botulinum neurotoxin type A on urinary NGF, TGF BETA-1, TIMP-2 levels in children with neurogenic detrusor overactivity due to myelodysplasia. <i>Neurourology and Urodynamics</i> , 2017, 36, 1896-1902.	0.8	14
304	Surgical Considerations in Neurogenic Bladder. , 2017, , 329-341.		0
305	Chronic Migraine: An Update on Physiology, Imaging, and the Mechanism of Action of Two Available Pharmacologic Therapies. <i>Headache</i> , 2017, 57, 109-125.	1.8	115
306	Botulinum Neurotoxins: Biology, Pharmacology, and Toxicology. <i>Pharmacological Reviews</i> , 2017, 69, 200-235.	7.1	506
307	Urodynamic prognostic factors for large post-void residual urine volume after intravesical injection of onabotulinumtoxinA for overactive bladder. <i>Scientific Reports</i> , 2017, 7, 43753.	1.6	14
308	OnabotulinumtoxinA for the Treatment of Patients with Overactive Bladder and Urinary Incontinence: Results of a Phase 3, Randomized, Placebo Controlled Trial. <i>Journal of Urology</i> , 2017, 197, S216-S223.	0.2	133
309	Morphological changes in different populations of bladder afferent neurons detected by herpes simplex virus (HSV) vectors with cell-type-specific promoters in mice with spinal cord injury. <i>Neuroscience</i> , 2017, 364, 190-201.	1.1	17
310	Changes in Management of Poorly Compliant Bladder in Botulinum Toxin A Era. <i>Current Urology Reports</i> , 2017, 18, 64.	1.0	6
311	Potential applications of lowâ€energy shock waves in functional urology. <i>International Journal of Urology</i> , 2017, 24, 573-581.	0.5	33
312	Re: Reduction of Urgency Severity is the Most Important Factor in the Subjective Therapeutic Outcome of Intravesical OnabotulinumtoxinA Injection for Overactive Bladder. <i>Journal of Urology</i> , 2017, 198, 748-752.	0.2	0
313	Overactive bladder treatment: application of methylene blue to improve the injection technique of onabotulinum toxin A. <i>Scandinavian Journal of Urology</i> , 2017, 51, 474-478.	0.6	8
314	Nerve growth factor release from the urothelium increases via activation of bladder Câ€fiber in rats with cerebral infarction. <i>Neurourology and Urodynamics</i> , 2017, 36, 1448-1455.	0.8	9
315	Mucosal modulation of contractility in bladder strips from normal and overactive rat models and the effect of botulinum toxin A on overactive bladder strips. <i>Neurourology and Urodynamics</i> , 2017, 36, 1052-1060.	0.8	5
316	Expressions of urothelial functional proteins in idiopathic detrusor overactivity patients refractory to antimuscarinic therapy with different urodynamic characteristics. <i>Neurourology and Urodynamics</i> , 2017, 36, 1313-1319.	0.8	2
317	Intravesical Botulinum Toxin for Neurogenic Bladderâ€“Can We Just Irrigate the Bladder with Botulinumtoxin?. <i>Current Bladder Dysfunction Reports</i> , 2017, 12, 343-348.	0.2	0

#	ARTICLE	IF	CITATIONS
318	Purinergic Signalling: Therapeutic Developments. <i>Frontiers in Pharmacology</i> , 2017, 8, 661.	1.6	302
319	Topical Review: Potential Use of Botulinum Toxin in the Management of Painful Posttraumatic Trigeminal Neuropathy. <i>Journal of Oral and Facial Pain and Headache</i> , 2017, 31, 7-18.	0.7	13
320	Botulinum Toxin Versus Neural Stimulation. <i>European Urology Focus</i> , 2017, 3, 530-532.	1.6	0
321	Botulinum toxin: A review of the mode of action in migraine. <i>Acta Neurologica Scandinavica</i> , 2018, 137, 442-451.	1.0	44
322	Advances in intravesical therapy for bladder pain syndrome (BPS)/interstitial cystitis (IC). <i>LUTS: Lower Urinary Tract Symptoms</i> , 2018, 10, 3-11.	0.6	32
323	TRPV1 enhances the afferent response to P2X receptor activation in the mouse urinary bladder. <i>Scientific Reports</i> , 2018, 8, 197.	1.6	36
324	Safety and Feasibility of Intravesical Instillation of Botulinum Toxin-A in Hydrogel-based Slow-release Delivery System in Patients With Interstitial Cystitis-Bladder Pain Syndrome: A Pilot Study. <i>Urology</i> , 2018, 114, 60-65.	0.5	36
325	Autonomic dysreflexia after spinal cord injury: Systemic pathophysiology and methods of management. <i>Autonomic Neuroscience: Basic and Clinical</i> , 2018, 209, 59-70.	1.4	162
326	Neurogenic Bladder Pathophysiology. , 2018, , 7-16.		1
327	The binding of botulinum neurotoxins to different peripheral neurons. <i>Toxicon</i> , 2018, 147, 27-31.	0.8	10
328	A Pilot Study to Evaluate the Efficacy and Safety of Treatment with Botulinum Toxin in Patients with Recalcitrant and Persistent Erythematotelangiectatic Rosacea. <i>Annals of Dermatology</i> , 2018, 30, 688.	0.3	13
329	Pharmacological differences and clinical implications of various botulinum toxin preparations: a critical appraisal. <i>Functional Neurology</i> , 2018, 33, 7.	1.3	27
330	Minimally Invasive Treatments. , 2018, , 387-404.		0
331	Clinical outcomes of intravesical injections of botulinum toxin type A in patients with refractory idiopathic overactive bladder. <i>Pharmacological Reports</i> , 2018, 70, 1133-1138.	1.5	3
332	A Study and Review of Effects of Botulinum Toxins on Mast Cell Dependent and Independent Pruritus. <i>Toxins</i> , 2018, 10, 134.	1.5	12
333	Therapeutic Approaches of Botulinum Toxin in Gynecology. <i>Toxins</i> , 2018, 10, 169.	1.5	14
334	Epidemiology and pathophysiology of neurogenic bladder after spinal cord injury. <i>World Journal of Urology</i> , 2018, 36, 1517-1527.	1.2	119
335	Intradetrusor onabotulinumtoxinA injections are significantly more efficacious than oral oxybutynin for treatment of neurogenic detrusor overactivity: results of a randomized, controlled, 24-week trial. <i>Einstein (Sao Paulo, Brazil)</i> , 2018, 16, eAO4207.	0.3	10

#	ARTICLE	IF	CITATIONS
336	What is the exact working mechanism of botulinum toxin A and sacral nerve stimulation in the treatment of overactive bladder/detrusor overactivity? ICIâ€RS 2017. <i>Neurourology and Urodynamics</i> , 2018, 37, S108-S116.	0.8	22
337	Development of stress-induced bladder insufficiency requires functional TRPV1 channels. <i>American Journal of Physiology - Renal Physiology</i> , 2018, 315, F1583-F1591.	1.3	12
338	Agents in early development for treatment of bladder dysfunction â€“ promise of drugs acting at TRP channels?. <i>Expert Opinion on Investigational Drugs</i> , 2019, 28, 749-755.	1.9	21
339	Using Botulinum Toxin A for Treatment of Interstitial Cystitis/Bladder Pain Syndromeâ€”Possible Pathomechanisms and Practical Issues. <i>Toxins</i> , 2019, 11, 641.	1.5	8
340	The Botulinum Treatment of Neurogenic Detrusor Overactivity: The Double-Face of the Neurotoxin. <i>Toxins</i> , 2019, 11, 614.	1.5	10
341	The Management of Urine Storage Dysfunction in the Neurological Patient. <i>SN Comprehensive Clinical Medicine</i> , 2019, 1, 160-182.	0.3	7
342	TRP Channels as Lower Urinary Tract Sensory Targets. <i>Medical Sciences (Basel, Switzerland)</i> , 2019, 7, 67.	1.3	25
343	The Current Role of Botox in a Pediatric Neurogenic Bladder Condition. <i>Current Bladder Dysfunction Reports</i> , 2019, 14, 115-123.	0.2	3
344	Outcome of Botulinum Toxinâ€™A intraprostatic injection for benign prostatic hyperplasia induced lower urinary tract symptoms: A prospective multicenter study. <i>Prostate</i> , 2019, 79, 1221-1225.	1.2	2
345	Characterisation of urinary monocyte chemoattractant protein 1: Potential biomarker for patients with overactive bladder. <i>Arab Journal of Urology Arab Association of Urology</i> , 2019, 17, 58-60.	0.7	4
346	Pharmacology of the Lower Urinary Tract. , 2019, , 79-111.		2
348	Visceral Pain and Hypersensitivity Disorders. , 2019, , 131-139.		0
349	Botulinum Toxin Injections in the Bladder and Urethral Sphincter. , 2019, , 291-298.		0
350	Nerve sprouting and neurogenic inflammation characterize the neurogenic detrusor overactive bladder of patients no longer responsive to drug therapies. <i>Journal of Cellular and Molecular Medicine</i> , 2019, 23, 4076-4087.	1.6	11
351	Evidence and experience with onabotulinumtoxinA in chronic migraine: Recommendations for daily clinical practice. <i>NeurologÃa (English Edition)</i> , 2019, 34, 408-417.	0.2	2
352	Intravesical Chemodenervation and Toxins. , 2019, , 177-204.		0
353	Pathophysiology of Overactive Bladder. , 2019, , 1-12.		0
354	Single onabotulinumtoxinA 200U dose improved clinical symptoms but not urothelial dysfunction in neurogenic detrusor overactivity due to spinal cord injury. <i>Journal of the Formosan Medical Association</i> , 2019, 118, 125-133.	0.8	3

#	ARTICLE	IF	CITATIONS
355	Evidencia y experiencia de b <sup>3</sup> tox en migra <sup>3</sup> a cr <sup>3</sup> nica: Recomendaciones para la pr <sup>3</sup> ctica cl <sup>3</sup> nica diaria. Neurolog <sup>3</sup> a, 2019, 34, 408-417.	0.3	11
356	Evidencia y experiencia del uso de onabotulinumtoxinA en neuralgia del trig <sup>3</sup> mino y cefaleas primarias distintas de la migra <sup>3</sup> a cr <sup>3</sup> nica. Neurolog <sup>3</sup> a, 2020, 35, 568-578.	0.3	12
357	Focal arm weakness following intradetrusor botulinum toxin administration in spinal cord injury: Report of two cases. Journal of Spinal Cord Medicine, 2020, 43, 904-907.	0.7	1
358	P2X3-Containing Receptors as Targets for the Treatment of Chronic Pain. Neurotherapeutics, 2020, 17, 826-838.	2.1	32
359	Neuroimmune System as a Driving Force for Plasticity Following CNS Injury. Frontiers in Cellular Neuroscience, 2020, 14, 187.	1.8	25
360	Low energy shock wave <sup>3</sup> delivered intravesical botulinum neurotoxin <sup>3</sup> A potentiates antioxidant genes and inhibits proinflammatory cytokines in rat model of overactive bladder. Neurourology and Urodynamics, 2020, 39, 2447-2454.	0.8	11
361	Evidence of and experience with the use of onabotulinumtoxinA in trigeminal neuralgia and primary headaches other than chronic migraine. Neurolog <sup>3</sup> a (English Edition), 2020, 35, 568-578.	0.2	0
362	Therapeutic Effect of Botulinum Toxin A on Sensory Bladder Disorders <sup>3</sup> From Bench to Bedside. Toxins, 2020, 12, 166.	1.5	10
363	The Urothelium: Life in a Liquid Environment. Physiological Reviews, 2020, 100, 1621-1705.	13.1	92
364	Mechanism of Action of OnabotulinumtoxinA in Chronic Migraine: A Narrative Review. Headache, 2020, 60, 1259-1272.	1.8	95
365	Mechanism of Action of Botulinum Toxin A in Treatment of Functional Urological Disorders. Toxins, 2020, 12, 129.	1.5	25
366	Neuronal selectivity of botulinum neurotoxins. Toxicon, 2020, 178, 20-32.	0.8	23
367	OnabotulinumtoxinA (botulinum toxin type <sup>3</sup> A) for the treatment of Japanese patients with overactive bladder and urinary incontinence: Results of single <sup>3</sup> dose treatment from a phase <sup>3</sup> III, randomized, double <sup>3</sup> blind, placebo <sup>3</sup> controlled trial (interim analysis). International Journal of Urology, 2020, 27, 227-234.	0.5	22
368	Chronic Pelvic Pain and Pelvic Dysfunctions. Urodynamics, Neurourology and Pelvic Floor Dysfunctions, 2021, , .	0.0	2
369	Physiopathology of Overactive Bladder. Urodynamics, Neurourology and Pelvic Floor Dysfunctions, 2021, , 1-11.	0.0	0
370	Will repeated botulinum toxin A improve detrusor overactivity and bladder compliance in patients with chronic spinal cord injury?. Tzu Chi Medical Journal, 2021, 33, 101.	0.4	6
371	The Effect of Low-Intensity Extracorporeal Shockwave Treatment on the Urinary Bladder in an Experimental Diabetic Rat Model. International Neurourology Journal, 2021, 25, 34-41.	0.5	4
372	Subjective Efficacy of Suburothelial Versus Intradetrusor Botulinum Toxin for Overactive Bladder: A Retrospective Cohort Study. Journal of Gynecologic Surgery, 0, , .	0.0	0

#	ARTICLE	IF	CITATIONS
373	Purinergic signalling in the urinary bladder – When function becomes dysfunction. <i>Autonomic Neuroscience: Basic and Clinical</i> , 2021, 235, 102852.	1.4	6
374	Interventions for chronic pruritus of unknown origin. <i>The Cochrane Library</i> , 2020, 1, CD013128.	1.5	24
375	Clinical Use of Botulinum Neurotoxin: Urogenital Disorders Including Overactive Bladder. , 2014, , 123-152.		1
376	Current Pharmacologic Treatment of Lower Urinary Tract Symptoms. <i>Current Clinical Urology</i> , 2014, , 121-222.	0.0	1
377	Modulation of Urinary Bladder Innervation: TRPV1 and Botulinum Toxin A. <i>Handbook of Experimental Pharmacology</i> , 2011, , 345-374.	0.9	9
378	Physiology and Pharmacology of the Bladder and Urethra. , 2012, , 1786-1833.e17.		22
379	Presence of Cleaved Synaptosomal-Associated Protein-25 and Decrease of Purinergic Receptors P2X3 in the Bladder Urothelium Influence Efficacy of Botulinum Toxin Treatment for Overactive Bladder Syndrome. <i>PLoS ONE</i> , 2015, 10, e0134803.	1.1	14
380	Long-Term Effects of Botulinum Toxin Complex Type A Injection on Mechano- and Metabo-Sensitive Afferent Fibers Originating from Gastrocnemius Muscle. <i>PLoS ONE</i> , 2015, 10, e0140439.	1.1	6
381	Factors Associated with Therapeutic Efficacy of Intravesical OnabotulinumtoxinA Injection for Overactive Bladder Syndrome. <i>PLoS ONE</i> , 2016, 11, e0147137.	1.1	28
382	Experience with different botulinum toxins for the treatment of refractory neurogenic detrusor overactivity. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2010, 36, 66-74.	0.7	14
383	Pharmacology, immunology, and current developments. <i>Series in Cosmetic and Laser Therapy</i> , 2011, , 1-14.	0.0	2
384	Use of botulinum toxin in paediatric urology. <i>Urologie Pro Praxi</i> , 2019, 20, 9-12.	0.0	1
385	Biomaterials in urinary incontinence and treatment of their complications. <i>Indian Journal of Urology</i> , 2010, 26, 221.	0.2	11
386	The surgical management of the refractory overactive bladder. <i>Indian Journal of Urology</i> , 2010, 26, 263.	0.2	4
387	How botulinum toxin in neurogenic detrusor overactivity can reduce upper urinary tract damage?. <i>World Journal of Nephrology</i> , 2016, 5, 195.	0.8	6
388	Towards New Therapies for Parkinson's Disease. , 2011, , .		10
389	Development and Validation of the Actionable Bladder Symptom Screening Tool for Multiple Sclerosis Patients. <i>International Journal of MS Care</i> , 2013, 15, 182-192.	0.4	39
390	Wat zijn de langetermijneffecten van botulinum toxine-A bij overactieve blaas?. , 2006, , 3315-3317.		0

#	ARTICLE	IF	CITATIONS
391	Management of lower urinary tract symptoms in men with progressive neurological disease. Current Opinion in Urology, 2006, 16, 30-36.	0.9	6
392	Botulinum Toxin: An Effective Treatment for Urge Incontinence. , 2009, , 257-274.		0
393	Neurophysiology of Micturition: What's New?. , 2009, , 17-33.		0
394	Minimally Invasive Therapy for Neurogenic Detrusor Overactivity: A Review. UroToday International Journal, 2009, 02, .	0.1	0
395	Uso de la toxina botulnica en el tratamiento de los trastornos del tracto urinario inferior: Situaci3n actual. Archivos Espanoles De Urologia, 2010, 63, .	0.1	1
397	Biology and Mechanism of Action. , 2011, , 13-26.		1
399	Botulinum Toxin Treatment in Bladder Pain Syndrome. , 2013, , 321-327.		0
400	Allgemeine operative Therapie bei Patienten mit neurogenen. , 2014, , 1-10.		0
401	Intravesical Therapy for Refractory Overactive Bladder and Detrusor Overactivity in Adults: Botulinum Toxin-A. Current Clinical Urology, 2014, , 135-154.	0.0	0
402	Allgemeine operative Therapie bei Patienten mit neurogenen Blasenfunktionsstrungen. , 2016, , 1029-1035.		0
403	Botulinum Toxin in Treatment of Bladder Pain Syndrome/Interstitial Cystitis. , 2018, , 101-104.		0
404	Interventions for pruritus of unknown cause. The Cochrane Library, 0, , .	1.5	2
405	Transient Receptor Potential Channels and Botulinum Neurotoxins in Chronic Pain. Frontiers in Molecular Neuroscience, 2021, 14, 772719.	1.4	7
406	Intravesical Botulinum Toxin for the Treatment of Overactive Bladder. , 2021, , 365-373.		0
408	Botulinum Toxin Injections to Treat Neurogenic Bladder " Sphincter Dysfunction in Pediatric Patients. , 2006, , 199-202.		0
409	Urological Applications. , 2007, , 167-193.		0
410	Darifenacin: a selective M3muscarinic receptor antagonist for the treatment of overactive bladder. Therapy: Open Access in Clinical Medicine, 2006, 3, 723-732.	0.2	0
413	Botulinum toxin for the treatment of idiopathic and neurogenic overactive bladder: state of the art. Reviews in Urology, 2006, 8, 198-208.	0.9	28

#	ARTICLE	IF	CITATIONS
414	Can urinary nerve growth factor be a biomarker for overactive bladder?. <i>Reviews in Urology</i> , 2010, 12, e69-77.	0.9	45
415	Treatment of painful bladder syndrome/interstitial cystitis with botulinum toxin A: why isn't it effective in all patients?. <i>Translational Andrology and Urology</i> , 2015, 4, 543-54.	0.6	2
416	BoNT/A in the Urinary Bladder – More to the Story than Silencing of Cholinergic Nerves. <i>Toxins</i> , 2022, 14, 53.	1.5	5
417	BoNT/A1 Secondary Failure for the Treatment of Neurogenic Detrusor Overactivity: An Ex Vivo Functional Study. <i>Toxins</i> , 2022, 14, 77.	1.5	0
418	Toxina botulnica: efecto analgsico pluripotencial. <i>Revista De La Sociedad Espanola Del Dolor</i> , 2022, , .	0.0	0
419	Hengli Chinese Botulinum Toxin Type A for Treatment of Patients With Overactive Bladder: A Multicenter, Prospective, Randomized, Double-Blind, Placebo-Controlled Trial. <i>Frontiers in Pharmacology</i> , 2022, 13, 840695.	1.6	3
420	Botulinum Neurotoxin Uses in Overactive Bladder. , 0, , .		0
421	Botulinum Toxin for Neurogenic and Non-neurogenic Bladder Pain. <i>Current Bladder Dysfunction Reports</i> , 2022, 17, 38-47.	0.2	0
422	OnabotulinumtoxinA alters inflammatory gene expression and immune cells in chronic headache patients. <i>Brain</i> , 2022, 145, 2436-2449.	3.7	12
423	Overactive Bladder Symptoms Within Nervous System: A Focus on Etiology. <i>Frontiers in Physiology</i> , 2021, 12, 747144.	1.3	3
424	Urinary Biomarkers in Interstitial Cystitis/Bladder Pain Syndrome and Its Impact on Therapeutic Outcome. <i>Diagnostics</i> , 2022, 12, 75.	1.3	16
425	Neurophysiology of Micturition: Whats New?. , 2009, , 17-33.		0
426	Botulinum Toxin: An Effective Treatment for Urge Incontinence. , 2009, , 257-274.		0
430	Efficacy and Safety of Botulinum Toxin A and Pulsed Radiofrequency on Postherpetic Neuralgia: A Randomized Clinical Trial. <i>Contrast Media and Molecular Imaging</i> , 2022, 2022, 1-9.	0.4	3
431	Nano-BTA: A New Strategy for Intravesical Delivery of Botulinum Toxin A. <i>International Neurourology Journal</i> , 2022, 26, 92-101.	0.5	1
432	Clinical Application of Botulinum Neurotoxin in Lower-Urinary-Tract Diseases and Dysfunctions: Where Are We Now and What More Can We Do?. <i>Toxins</i> , 2022, 14, 498.	1.5	8
433	Refractory pruritic Fox-Fordyce disease successfully treated with botulinum toxin type A. <i>International Journal of Women's Dermatology</i> , 2022, 8, e039.	1.1	1
434	Allgemeine operative Therapie bei Patienten mit neurogenen Blasenfunktionsstrungen. <i>Springer Reference Medizin</i> , 2022, , 1-7.	0.0	0

#	ARTICLE	IF	CITATIONS
435	Acute Intravesical Capsaicin for the Study of TRPV1 in the Lower Urinary Tract: Clinical Relevance and Potential for Innovation. <i>Medical Sciences (Basel, Switzerland)</i> , 2022, 10, 50.	1.3	0
436	How Does Botulinum Toxin Inhibit Itch?. <i>Toxins</i> , 2022, 14, 701.	1.5	2
437	Intravesical injection of botulinum toxin type a may be an effective treatment option for autonomic dysreflexia in patients with high-level spinal cord injury. <i>Journal of Spinal Cord Medicine</i> , 2024, 47, 74-78.	0.7	2
438	Effect of Bladder Injection of OnabotulinumtoxinA on the Central Expression of Genes Associated with the Control of the Lower Urinary Tract: A Study in Normal Rats. <i>International Journal of Molecular Sciences</i> , 2022, 23, 14419.	1.8	2
439	Liposome-Encapsulated Botulinum Toxin A in Treatment of Functional Bladder Disorders. <i>Toxins</i> , 2022, 14, 838.	1.5	2
440	Effects of Botulinum Toxin Type A on the Nociceptive and Lemniscal Somatosensory Systems in Chronic Migraine: An Electrophysiological Study. <i>Toxins</i> , 2023, 15, 76.	1.5	5
441	Real-Time Documentation of the Effect of Onabotulinumtoxin A Detrusor Injection in OAB Patientsâ€™Preliminary Results. <i>Toxins</i> , 2023, 15, 30.	1.5	2
442	Botulinum Toxin Type A for Refractory Neurogenic Detrusor Overactivity in Spinal Cord Injured Patients in Singapore. <i>Annals of the Academy of Medicine, Singapore</i> , 2007, 36, 11-17.	0.2	19
443	Botulinum Toxin A Injection for Autonomic Dysreflexiaâ€™Detrusor Injection or Urethral Sphincter Injection?. <i>Toxins</i> , 2023, 15, 108.	1.5	1
444	Pharmacology of the Lower Urinary Tract. , 2022, , 1-9.		0
445	OnabotulinumtoxinA effects on trigeminal nociceptors. <i>Cephalalgia</i> , 2023, 43, 033310242211416.	1.8	3
446	Botulinum Toxin Therapy for Bladder Pain Syndrome/Interstitial Cystitis. <i>Current Bladder Dysfunction Reports</i> , 0, , .	0.2	0
447	Role of Urological Botulinum Toxin-A Injection for Overactive Bladder and Voiding Dysfunction in Patients with Parkinsonâ€™s Disease or Post-Stroke. <i>Toxins</i> , 2023, 15, 166.	1.5	5
448	Botulinum Toxin Injections in the Bladder and Urethral Sphincter. , 2023, , 1-10.		0
450	Current and Emerging Pharmacological Targets and Treatments of Urinary Incontinence and Related Disorders. <i>Pharmacological Reviews</i> , 2023, 75, 554-674.	7.1	14
451	Intravesical Injection of Botulinum Toxin Type A in Men without Bladder Outlet Obstruction and Post-Deobstructive Prostate Surgery. <i>Toxins</i> , 2023, 15, 221.	1.5	2
452	Skin sympathetic nerve activity as a potential biomarker for overactive bladder. <i>World Journal of Urology</i> , 0, , .	1.2	0
453	How treatment of lower urinary tract symptoms can benefit from basic research. , 2023, , 105-120.		0



#	ARTICLE	IF	CITATIONS
456	Allgemeine operative Therapie bei Patienten mit neurogenen Blasenfunktionsstörungen. Springer Reference Medizin, 2023, , 1935-1941.	0.0	0
464	Pharmacology of the Lower Urinary Tract. , 2023, , 107-115.		0
465	Botulinum Toxin Injections in the Bladder and Urethral Sphincter. , 2023, , 401-410.		0
467	OnabotulinumtoxinA: Discussion of the evidence for effectiveness of OnabotulinumA and its place in chronic migraine treatment. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2024, , 87-106.	1.0	0